Vagus nerve stimulation (VNS) uses controlled electrical impulses to modulate the activity of the vagus nerve — the longest cranial nerve in the body and the primary channel of the parasympathetic nervous system. What began in the 1990s as an experimental epilepsy treatment has expanded into one of the most versatile tools in modern medicine. With FDA-approved indications now spanning epilepsy, depression, stroke rehabilitation, and rheumatoid arthritis, and a growing body of evidence for dozens of other conditions, VNS sits at the center of a broader shift toward bioelectronic medicine — treating disease by modulating neural circuits rather than relying solely on drugs.
How Vagus Nerve Stimulation Works
The vagus nerve connects the brainstem to the heart, lungs, gut, and immune organs. Roughly 80% of its fibers are afferent — carrying information from the body to the brain. VNS works by delivering electrical pulses to these fibers, which travel upstream to influence brain regions involved in seizure activity, mood regulation, pain perception, and inflammation. The nerve also carries efferent signals that modulate heart rate, gut motility, and the inflammatory reflex — a pathway where vagal signaling instructs the spleen to suppress pro-inflammatory cytokines like TNF.
This dual-pathway architecture is why VNS can address such a broad range of conditions: it changes what the body tells the brain (afferent modulation) and what the brain tells the organs (efferent modulation) simultaneously.
Types of Vagus Nerve Stimulation
Implanted VNS
The traditional approach involves surgically placing a small pulse generator beneath the skin of the left chest, connected by a lead wire wrapped around the left cervical vagus nerve. The device delivers regular electrical pulses on a programmable schedule — typically 30 seconds of stimulation every 5 minutes, 24 hours a day. Patients can also trigger additional stimulation by swiping a magnet over the device when they feel a seizure coming on. The surgery is performed under general anesthesia, typically as an outpatient procedure lasting 1–2 hours.
Closed-Loop (Responsive) VNS
Newer implanted devices incorporate cardiac sensing to detect the rapid heart rate surge (ictal tachycardia) that accompanies over 80% of seizures. When the device detects this surge, it delivers an automatic extra stimulation burst to interrupt the seizure in real time, in addition to its baseline scheduled stimulation. A 2026 retrospective study from Xuanwu Hospital comparing closed-loop and open-loop VNS in 81 patients with drug-resistant epilepsy found a responder rate of 75.7% with closed-loop stimulation versus 43.2% with open-loop — a clinically meaningful difference, though prospective randomized trials are still needed to confirm the finding.
Transcutaneous VNS (tVNS)
Non-invasive VNS stimulates the vagus nerve through the skin, without surgery. Two main approaches exist:
- Transcutaneous auricular VNS (taVNS) targets the auricular branch of the vagus nerve in the outer ear — typically the tragus or cymba conchae — using small electrode clips or earpieces. This is the most widely studied non-invasive approach and the basis for most consumer-grade VNS devices.
- Transcutaneous cervical VNS (tcVNS) applies stimulation to the vagus nerve through the skin of the neck using a handheld device. The gammaCore device, which uses this approach, is FDA-cleared for cluster headache and migraine.
A 2026 editorial in Frontiers in Neuroscience described non-invasive VNS as an emerging “platform technology for bioelectronic medicine,” citing growing evidence for applications in inflammation, cognition, sleep, metabolic regulation, and perioperative care. The editorial proposed a care model in which VNS works alongside conventional drugs rather than replacing them, with a focus on restoring physiological balance rather than suppressing symptoms.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Clinician-applied tVNS
- Implanted VNS and neuromodulation
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
FDA-Approved Indications
VNS has accumulated four FDA approvals over three decades, each expanding the technology into a new therapeutic domain:
- Drug-resistant epilepsy (1997) — The first FDA approval, for patients aged 12 and older whose seizures are not adequately controlled by medication. Long-term data consistently show that approximately 50% of patients achieve a 50% or greater reduction in seizure frequency within two years, with efficacy continuing to improve over time. VNS does not typically eliminate seizures entirely but can meaningfully reduce their frequency and severity.
- Treatment-resistant depression (2005) — Approved for patients who have not responded to at least four adequate antidepressant treatments. VNS modulates brain regions involved in mood regulation, including the locus coeruleus, limbic system, and prefrontal cortex. A European study found that efficacy increased progressively over 12 months, with the European sample showing significantly greater symptom reduction than an earlier American cohort using a similar protocol.
- Ischemic stroke rehabilitation (2021) — VNS paired with intensive rehabilitation exercises received FDA approval to improve upper limb motor function after ischemic stroke. The approach is based on the principle that vagal stimulation during rehabilitation enhances neuroplasticity — the brain’s ability to reorganize and form new neural connections.
- Rheumatoid arthritis (2025) — The most recent and arguably most consequential approval. In July 2025, the FDA approved the SetPoint System (SetPoint Medical), an implantable neurostimulator roughly the size of a vitamin tablet that stimulates the vagus nerve for just 60 seconds once daily. The device activates the body’s cholinergic anti-inflammatory pathway — a mechanism where vagal signaling instructs immune cells in the spleen to reduce production of inflammatory cytokines. In the double-blind, placebo-controlled RESET-RA trial, patients with one prior biologic or targeted synthetic DMARD achieved ACR20 response rates of 44.2% versus 19% in controls at 12 weeks, with a treatment-related serious adverse event rate of just 1.6%. This was the first FDA approval targeting inflammation rather than the brain, marking a pivotal step for bioelectronic medicine as a field.
Emerging Applications Under Investigation
Beyond its approved indications, VNS is being studied across a remarkably diverse range of conditions. While evidence for many of these applications is still early-stage, the breadth of investigation reflects the vagus nerve’s role as a master regulator across multiple organ systems:
- Heart failure — VNS may counteract the autonomic imbalance (heightened sympathetic, diminished parasympathetic activity) that drives heart failure progression. Early clinical trials demonstrated the feasibility and safety of right vagus stimulation in advanced heart failure patients, with improvements in ejection fraction and symptom reduction.
- Alzheimer’s disease and cognitive decline — Both implanted VNS and taVNS are being explored for cognitive enhancement. A 2025 pilot study found that taVNS improved encoding during short-term memory tasks, and multiple trials are investigating its effects on mild cognitive impairment.
- Post-traumatic stress disorder (PTSD) — Transcutaneous cervical VNS has shown preliminary benefits in reducing PTSD symptoms, with improvements in declarative and working memory in pilot studies.
- Inflammatory bowel disease — The same anti-inflammatory pathway targeted in the RA approval is being investigated for Crohn’s disease and ulcerative colitis, where chronic vagal modulation may help control gut inflammation.
- Anxiety disorders — Multiple clinical trials are currently enrolling for taVNS in social anxiety disorder and generalized anxiety, with mechanisms centered on vagal modulation of the brain’s emotional processing centers.
- Metabolic regulation — Emerging evidence suggests VNS may influence blood glucose regulation and offer therapeutic potential in type 2 diabetes, possibly through vagal effects on gut hormones and pancreatic function.
- Sleep disorders — Research from 2024–2025 indicates that taVNS may help restore circadian rhythm and improve sleep quality through effects on melatonin release and autonomic balance.
- Perioperative care — Early case reports and hypothesis studies suggest VNS may reduce post-operative pain and fatigue, particularly in elderly and frail patient populations.
The VNS Implantation Process
For patients receiving implanted VNS, the process follows a well-established pathway:
Pre-implantation evaluation. A comprehensive neurological assessment including brain imaging, EEG monitoring, medication history review, and evaluation of overall health. The clinical team determines whether VNS is appropriate based on the patient’s specific condition, treatment history, and potential risks.
Surgical implantation. The pulse generator is placed in a small subcutaneous pocket in the left chest wall. A lead wire is tunneled under the skin to the neck, where it is carefully wrapped around the left cervical vagus nerve. The procedure is typically performed under general anesthesia and takes 1–2 hours. Most patients go home the same day or the next morning.
Programming and titration. Two to four weeks after surgery, the medical team begins programming the device using a handheld controller. Stimulation parameters — frequency, pulse width, current intensity, and on/off cycle timing — are gradually adjusted over several visits to find the optimal settings for each patient. This titration process typically takes weeks to months.
Ongoing monitoring. Regular follow-up appointments track treatment response, adjust stimulation settings as needed, and monitor for any device-related issues. The generator battery typically lasts 3–8 years depending on stimulation settings, after which it can be replaced in a minor outpatient procedure.
Risks and Side Effects
VNS is generally well tolerated, but carries risks that patients should discuss with their medical team:
Surgical risks include infection, bleeding, nerve injury, and reactions to anesthesia. These are uncommon with experienced surgical teams but not negligible.
Stimulation-related side effects are the most frequently reported. Hoarseness or voice changes during stimulation periods are the most common, occurring in a significant minority of patients. Coughing, throat tingling, and shortness of breath during stimulation are also reported. These effects are typically mild, tend to decrease over time as the body adapts, and can often be reduced by adjusting stimulation parameters.
Device-related issues can include lead migration, device malfunction, or discomfort at the implant site. Regular monitoring and prompt reporting of unusual symptoms allow early detection and management.
Cardiac effects: Because the vagus nerve directly influences heart rate, VNS can cause bradycardia (abnormally slow heart rate) in rare cases. This is typically monitored during initial programming.
For non-invasive tVNS devices, the side-effect profile is considerably milder. Skin irritation at electrode sites, mild tingling, and occasional headache are the most commonly reported issues. However, consumer-grade tVNS devices are not yet standardized, and regulatory bodies are still developing guidelines for this rapidly growing category.
The Future of VNS
VNS is evolving along several fronts simultaneously. Closed-loop devices that respond to physiological signals in real time are showing markedly better results than traditional open-loop stimulation, at least in epilepsy. Miniaturization continues to shrink implantable devices — the SetPoint RA device is already the size of a vitamin tablet, a fraction of earlier pulse generators. Non-invasive approaches are expanding access beyond surgical candidates, and the clinical evidence base for taVNS is deepening across an extraordinary range of conditions.
Perhaps most significantly, the 2025 RA approval validated the concept of treating autoimmune disease by modulating neural circuits rather than systemically suppressing the immune system. This opens the door for VNS-based approaches to other inflammatory conditions — Crohn’s disease, lupus, psoriasis — and establishes bioelectronic medicine as a genuine therapeutic category alongside pharmacology and surgery. The next decade is likely to see VNS transition from a niche neurostimulation technique to a mainstream platform with applications across nearly every medical specialty.
Ready to dive deeper into the fascinating world of the vagus nerve and unlock even more secrets to your well-being? Discover the comprehensive guide in the “My Vagus Nerve & Me Book,” where you’ll explore the intricate details of this remarkable system. Learn how to naturally and artificially stimulate your vagus nerve, and gain insights into its crucial role in your immune system, digestion, heart rate, and mental health. Embrace the journey to enhanced well-being. Get My Vagus Nerve & Me eBook today and take the first step towards harnessing the power of your body’s most astonishing nerve.



